SEARCH

SEARCH BY CITATION

Keywords:

  • Puumala virus;
  • nephropathia epidemica;
  • myopic shift

Abstract

  1. Top of page
  2. Abstract
  3. Acknowledgement
  4. Transparency Declaration
  5. References

Clin Microbiol Infect 2012; 18: E435–E437

Abstract

Puumala virus infection causes epidemic nephropathia (NE), a certain type of haemorrhagic fever with renal syndrome (HFRS). Myopic shift is considered a pathognomonic sign of NE and HFRS but rates of ocular involvement vary. The aim of the study was to evaluate whether clinical and laboratory findings are associated with ophthalmic involvement in NE in Austria. We found that blurred vision and myopic shift are frequent in Puumala virus infections in Austria but are independent of disease severity.

The vast majority of European Hantavirus cases are caused by Puumala virus, carried by the bank vole and responsible for Nephropathia epidemica (NE) [1]. The aim of the study was to evaluate whether clinical and laboratory findings are associated with ophthalmic involvement and disease severity in NE in Austria.

Patients examined at the emergency room of the university hospital of Graz were eligible for study inclusion. Graz is located in the south-east of Austria where a vast majority of Austrian Puumala virus infections have been identified to date [2]. In the case of clinical suspicion of NE, diagnosis was established within 12 h after presentation using antibody testing (Point-of-care PUUMALA; Reagena, Toivala, Finland). Patients with a positive antibody test were examined by ophthalmologists within the same day. Ocular examination comprised determination of refraction (compared with baseline refraction) and best-corrected visual acuity, intraocular pressure using Goldmann applanation tonometry and split lamp examination. Patients were examined up to four times in certain cases until ocular manifestations returned to normal or to documented baseline refraction determined prior to NE. Body temperature was measured three times a day and additionally whenever the patient felt febrile. In addition, hypotension (<90 mmHG), bradycardia (<60 bpm) and tachycardia (>100 bpm) were measured three times a day. Furthermore, abnormal findings in liver function tests (AST, ALT), gamma-glutamyl transferase (GGT) and other laboratory parameters such as creatinine, urea, leukocytes, thrombocytes, CRP and LDH were assessed daily until discharge. The highest values (the lowest value for thrombocytes) were used for statistical calculations as described below.

Eighteen patients with NE (aged 18–68 years, median 40.5 years; two female, 16 male) were investigated. Patients had their first contact and investigation in the emergency room between day 1 and 14 (median, day 4) after onset of NE. Two patients had systemic symptoms (e.g. fever, cephalea, nausea) for 14 days prior to presentation and both had ophthalmic involvement. Myopic shift (=change in refraction power towards myopic direction) occurred in 9/18 (50%) patients; in eight in both eyes, in one patient in the left eye only. The average myopic shift was −2.75 diopters (maximum −3.50, minimum −1.50) in the right eye and −2.54 diopters (maximum −4.00, minimum −1.00) in the left eye. Blurred vision occurred in 14/18 (78%), conjunctival injection in 4/18 (22%), and subconjunctival haemorrhages in 1/18 (6%) patients. Intraocular pressure was normal in all eyes. All ocular manifestations were transient and did not require any treatment.

Fever (>37.8°C) was observed in 15/18 (83%) patients (median duration 7.5 days; minimum 0, maximum 15). The rates of bradycardia, tachycardia and hypotonia are depicted in Table 1. Three out of eighteen (17%) patients required haemodialysis; none of these three had myopic shift. Laboratory values are depicted in Table 2. There was no significant difference in clinical signs and symptoms and laboratory parameters between patients with and without myopic shift or with and without blurred vision (chi-square test for categorical variables; Mann–Whitney U-test for non-normally distributed continuous parameters). Only for C-reactive protein (CRP) was a difference found, with higher values measured in patients without blurred vision (p 0.03).

Table 1.   Clinical signs in patients with and without myopic shift/blurred vision
 Patients with myopic shift, %Patients without myopic shift, %p-valuePatients with blurred vision, %Patients without blurred vision, %p-value
Hypotonia (<90 mmHG syst)11 (1/9)0 (0/9)0.3037 (1/14)0 (0/4)0.582
Tachycardia (>100 bpm)11 (1/9)33 (3/9)0.25721 (3/14)25 (1/4)0.88
Bradycardia (<50 bpm)44 (4/9)33 (3/9)0.62936 (5/14)50 (2/4)0.605
Fever (>37.8°C)89 (8/9)78 (7/9)0.52786 (12/14)75 (3/4)0.612
Table 2.   Laboratory values in patients with and without myopic shift/blurred vision
Variable (normal range)Patients with myopic shift (n = 9); median (range)Patients without myopic shift (n = 9); median (range)p-valuePatients with blurred vision (n = 14); median (range)Patients without blurred vision (n = 4); median (range)p-value
  1. *CRP values higher in patients without blurred vision.

AST (<30) U/L61 (31–93)66 (26–193)0.26965 (26–193)88.5 (53–119)0.222
ALT (<35) U/L83 (20–134)84 (17–305)0.35383 (17–305)132.5 (67–233)0.089
GGT (<38) U/L93 (27–895)66 (16–377)1.00093 (16–895)90 (32–153)0.710
Creatinine (0.5–1) mg/dL3.5 (1.1–6.7)1.9 (0.8–10.2)0.5663.5 (0.8–10.2)3.75 (1.4–8.9)0.632
Urea (10–45) mg/dL137 (30–245)66 (21–207)0.310125 (21–245)90 (61–158)1.000
Leucocytes (4.4–11.3) G/L (highest value)11.98 (5.3–22.4)10.6 (5–13.6)0.69111.98 (4.98–22.41)10.41 (8.35–13.62)0.832
Thrombocytes (1140–440) G/L (lowest value)42 (25–138)83 (35–280)0.12251 (25–251)67.5 (35–280)0.559
CRP (<5) mg/L64 (1–134)66 (1–257)0.79163 (1–134)170 (66–257)0.026*
LDH (120–240) U/L281 (190–682)334 (165–550)0.791340 (165–682)295 (240–340)0.490

Myopic shift was less frequent in our study (50%) compared with a Finnish study (78%) [3]. On the other hand, the average myopic shift in our study (−2.75 diopters right eye, −2.54 diopters left eye) was more pronounced than in two other Finnish studies [3,4]. The rate of conjunctival haemorrhages in our study (6%) was similar to previous rates (2% and 4%, respectively) [3,5]. Conjunctival injection in our study (22%) resembled previous findings (27%) [5], but was lower compared with another Finnish study (87%) [3]. The frequency of ocular findings in Puumala virus infections seems to be diverse in different European countries, so local epidemiological data are necessary to interpret these clinical findings correctly. It is not clear whether differences in occurrence rates and in severity of ocular symptoms in different countries are due to variant virus strains, predisposition of inhabitants or diagnostic differences. The latter, however, is unlikely as the serological tests applied in our study (i.e. Point-of-care PUUMALA; Reagena) have also been used in previous European investigations [6,7]. In contrast to recent studies [3], we also evaluated patients with renal failure requiring haemodialysis and none had myopic shift. Previously, shallowing of the anterior chamber, thickening of the lens, changes in osmolarity of lens and aqueous humour, length of vitreous cavity and increased tissue permeability have been considered as possible mechanisms for ocular symptoms in NE [3]. Interestingly, one patient in our study presented myopic shift and decreased anterior chamber depth only in one eye. This is in contrast to the assumption that myopic shift is part of a systemic infection by Puumala virus [4]. This finding may argue for a local ocular manifestation as the causative pathogenesis of myopic shift in NE or reflects differences in time of resolution of myopic shift in both eyes. In four patients with blurred vision myopic shift was not detected. It is unclear whether this was due to the fact that refraction had already normalized at the time of examination or a slightly oedematous lens was still present, or was due to non-ophthalmic reasons in Puumala virus infections; one reason could be involvement of the CNS as previously published [6,8–11].

In conclusion, ocular symptoms (especially blurred vision and myopic shift) are frequent in Puumala virus infection in Austria and may therefore be important in diagnosis of the disease. Except for higher CRP values in patients without blurred vision, there was no difference in clinical variables and laboratory parameters in patients with or without blurred vision/myopic shift, suggesting that both are independent of disease severity in Puumala virus infections.

Acknowledgement

  1. Top of page
  2. Abstract
  3. Acknowledgement
  4. Transparency Declaration
  5. References

Parts of this study have been presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2010, Boston, USA.

Transparency Declaration

  1. Top of page
  2. Abstract
  3. Acknowledgement
  4. Transparency Declaration
  5. References

The authors declare no conflicts of interest.

References

  1. Top of page
  2. Abstract
  3. Acknowledgement
  4. Transparency Declaration
  5. References
  • 1
    Vapalahti O , Mustonen J , Lundkvist A , Henttonen H , Plyusnin A , Vaheri A . Hantavirus infections in europe . Lancet Infect Dis 2003 ; 3 : 653661 .
  • 2
  • 3
    Hautala N , Kauma H , Vapalahti O et al. Prospective study on ocular findings in acute puumala hantavirus infection in hospitalised patients . Br J Ophthalmol 2011 ; 95 : 559562 .
  • 4
    Kontkanen M , Puustjarvi T , Lahdevirta J . Myopic shift and its mechanism in nephropathia epidemica or puumala virus infection . Br J Ophthalmol 1994 ; 78 : 903906 .
  • 5
    Kontkanen M , Puustjarvi T , Kauppi P , Lahdevirta J . Ocular characteristics in nephropathia epidemica or puumala virus infection . Acta Ophthalmol Scand 1996 ; 74 : 621625 .
  • 6
    Hautala T , Hautala N , Mähönen SM et al. Young male patients are at elevated risk of developing serious central nervous system complications during acute Puumala hantavirus infection . BMC Infect Dis 2011 ; 11 : 217 .
  • 7
    Hautala T , Mähönen SM , Sironen T et al. Central nervous system-related symptoms and findings are common in acute Puumala hantavirus infection . Ann Med 2010 ; 42 : 344351 .
  • 8
    Krause R , Aberle S , Haberl R , Daxbock F , Wenisch C . Puumala virus infection with acute disseminated encephalomyelitis and multiorgan failure . Emerg Infect Dis 2003 ; 9 : 603605 .
  • 9
    Hoier S , Aberle SW , Langner C et al. Puumala virus RNA in patient with multiorgan failure . Emerg Infect Dis 2006 ; 12 : 356357 .
  • 10
    Alexeyev OA , Morozov VG . Neurological manifestations of hemorrhagic fever with renal syndrome caused by Puumala virus: review of 811 cases . Clin Infect Dis 1995 ; 20 : 255258 .
  • 11
    Ahlm C , Linden C , Linderholm M et al. Central nervous system and ophthalmic involvement in nephropathia epidemica (European type of haemorrhagic fever with renal syndrome) . J Infect 1998 ; 36 : 149155 .